UPLC-MS based urine untargeted metabolomic analyses to differentiate bladder cancer from renal cell carcinoma.

ABSTRACT: BACKGROUND:To discover biomarker panels that could distinguish cancers (BC and RCC) from healthy controls (HCs) and bladder cancers (BC) from renal cell carcinoma (RCC), regardless of whether the patients have haematuria. In addition, we also explored the altered metabolomic pathways of BC and RCC. METHODS:In total, 403 participants were enrolled in our study, which included 146 BC patients (77 without haematuria and 69 with haematuria), 115 RCC patients (94 without haematuria and 21 with haematuria) and 142 sex- and age-matched HCs. Their midstream urine samples were collected and analysed by performing UPLC-MS. The statistical methods and pathway analyses were applied to discover potential biomarker panels and altered metabolic pathways. RESULTS:The panel of α-CEHC, β-cortolone, deoxyino

SUBMITTER: Wang Z 

PROVIDER: S-EPMC6896793 | biostudies-literature | 2019 Dec

REPOSITORIES: biostudies-literature